跳到正文
GMP-Verlag LOGFILE Feature·· 7 天前AI 评分68

FDA 在 2026 PDA/FDA 联合监管会议举例说明设施设计对无菌保障的影响

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

AI 导读

FDA 在 2026 PDA/FDA 联合监管会议上以近期检查观察记录为例,说明现代化隔离器等屏障设备本身不能确保无菌保障。举例包括屏障系统内使用胶带与难清洁泡棉袖口、隔离器门密封圈用胶带修补、压差表失效、硅胶波纹管位置不当或变色,以及干预点难以到达致操作员在半压塞瓶上方进行高风险手动干预。

正文 · 原文

16.11.2026

  • LOGFILE Feature

Report from the PDA/FDA Joint Regulatory Conference 2026, excerpt from the GMP Compliance Adviser, Current topics

4 min. reading time | by by Sabine Paris, PhD
Published in LOGFILE 23/2026 

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.


Modern barrier systems and automation can substantially reduce contamination risks in aseptic processing. However, they only provide effective protection when facility design, maintenance and aseptic behaviour are properly aligned. Jason Chancey, Consumer Safety Officer in the Office of Manufacturing Quality at the FDA Center for Drug Evaluation and Research (CDER), illustrated this point at the 2026 PDA/FDA Joint Regulatory Conference using recent inspection observations. 

Examples observed by FDA included tape and difficult-to-clean foam cuffs inside barrier systems, an isolator door gasket repaired with tape, non-functional differential pressure gauges and improperly positioned or discoloured silicone bellows. These findings in critical areas demonstrate that equipment originally designed to provide appropriate protection may lose its effectiveness if damage, unsuitable repairs or maintenance deficiencies are not detected and corrected promptly. The type and scope of the outsourced activity(ies) must be agreed upon and defined between the parties involved.


Figure 1 | Tape and foam cuffs inside an isolator (Source: Jason Chancey, CDER, PDA/FDA Joint Regulatory Conference 2026)

Equipment and line design can also influence operator behaviour. Jason Chancey presented an example in which poor access to an intervention point led operators to perform high-risk manual interventions over partially stoppered vials. The issue was not limited to the operator’s actions: The position of the line made the intended access route difficult to use. Personnel and material flows, as well as access to foreseeable intervention points, should therefore be considered before equipment is installed. Retrofitted “mini-doors” in barrier systems may make an intervention less difficult, but they do not eliminate the associated contamination risk.


Abbildung 2 | High risk manual intervention (Source: Jason Chancey, CDER, PDA/FDA Joint Regulatory Conference 2026)

Caution is also required when using modular or “drop-in” cleanrooms. Such systems are not inherently unsuitable, but their acceptability depends on their design, airflow, surfaces and state of maintenance. Damaged ceiling panels, insufficient HEPA coverage or airflow directed from the operator back into the critical area may undermine the intended cleanroom performance. 


Common Weaknesses in Airflow Visualisation Studies 

Issues observed by FDA include:

  • tracer media with unsuitable buoyancy, density or dissipation characteristics,
  • excessive tracer-media velocity,
  • tracer media positioned away from the intervention being evaluated,
  • equipment or interventions that do not represent commercial conditions, and
  • airflow disturbances, vortices or short circuits that are not recognised and assessed. 

Airflow visualisation studies should represent actual operating conditions and include realistic interventions. Any visible airflow irregularity should be acknowledged and evaluated, even if it does not necessarily present a critical risk. 

Jason Chancey also cautioned against dismissing positive biological indicators following decontamination or sterilisation as “rogue indicators”. Such results require a complete investigation, potentially involving material, equipment and service suppliers. Repeating a test until an acceptable result is obtained is not a substitute for root-cause investigation and scientific evaluation.


Conclusion

The central message was that modern facility technology alone does not ensure sterility assurance. Barrier systems must be appropriately designed, continuously monitored and properly maintained. At the same time, interventions, airflow patterns and human behaviour must be considered realistically from the earliest stages of facility and line design.


Do you have any questions or suggestions? Please contact us at: redaktion@gmp-verlag.de

You may Also be Interested in the Following Articles

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

16.11.2026

FDA Findings: Safe Aseptic Manufacturing Starts With Facility Design

At the PDA/FDA Joint Regulatory Conference 2026, FDA made it clear that modern equipment alone does not ensure sterility assurance. The article examines GMP deficiencies identified during FDA inspections and the role of facility design in aseptic manufacturing.

Read more

Question of the Week | GMP-Verlag

16.11.2026

How is Qualification Carried out in Accordance with the V-model Described in GAMP® 5?

Here's the answer:

Read more

News: Medical Devices

13.11.2026

EMA: Harmonisation of Combination-Product Quality Assessment

EMA’s Combination Products Operational Group (COMBO) is working to improve alignment between notified body opinions (NBOps) and pharmaceutical quality assessment, according to its report on the meeting held on 8 October 2026.

Read more

PIC/S: Revision of the Framework for International Cooperation

13.11.2026

PIC/S: Revision of the Framework for International Cooperation

PIC/S has revised the framework governing its international cooperation. The updated Pharmaceutical Inspection Co-operation Scheme, PIC/S 1/95 (Rev. 7), was adopted in Istanbul on 2 November 2026 and entered into force on the same day.

Read more

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

06.11.2026

FDA Updates Framework for Coordinating Facility Evaluations and Inspections

FDA has revised its framework for collaboration between the Center for Drug Evaluation and Research (CDER) and the Office of Inspections and Investigations (OII). Version 2.0 of the Concept of Operations (ConOps), effective October 21, 2026, supersedes the original June 2017 version.

Read more

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

02.11.2026

Outsourced Activities in the GDP Environment Part III: Contract Giver and Contract Acceptor

For any outsourced GDP activity, there is a need for delimitation of responsibilities between a client (contract giver) and a contractor (contract acceptor). Read more about their roles and responsibilities in the following excerpt from GMP:KnowHow Pharmalogistics (GDP).

Read more

Previous

Next

Related Products

Skip product gallery

GMP Compliance Adviser | Named User Licence | 12M

GMP Compliance Adviser | Named User Licence | 12M

With an named user licence, one user can access the knowledge portal; with a corporate licence, any number of users can access it.Approx. 5,000 pages of practical GMP knowledge with illustrations and forms: Practical guidance for rapid implementation in the workplaceDetailed descriptions of GMP-compliant systemsInternational laws and guidelines Always up-to-date thanks to regular updates Download Advantages and Prices60+ Sample Documents In addition, the GMP Compliance Adviser contains more than 60 sample documents (MS Office) and practical examples that you can use.Sample SOPsSample FormsSample ReportsSample DocumentationChecklistsProcess Diagrams (Flowcharts)Practical Examples of QRM Application (e.g., Risk Analyses)Sample Documents for Qualification and ValidationCase StudiesWritten by more than 80 authors with hands-on experience directly linked to the industryA team of over 80 experts interpret regulatory requirements and describe how they are implemented in practice.The authors are experienced in the pharmaceutical industry, consulting, and government agencies.

delivery immediately after receipt of payment

€1,368.00 net excl. VAT

GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

GMP:KnowHow Pharma Logistics (GDP) | Named User Licence | 12M

Your knowledge portal for GDP-compliant pharmaceutical logistics.  It is important that you as a logistics service provider, but also as a client in the pharmaceutical industry, comply with regulatory requirements. The GMP:KnowHow knowledge portal guides you through the complex regulatory landscape of the pharmaceutical and logistical supply chain! The knowledge portal gives you an easy-to-understand overview of all the important topics. Interactive graphics help you navigate all areas covered by the EU GDP Guidelines (2013/C 343/01). You also have the relevant passages of the regulations directly at hand for each topic. This allows you to compare the requirements directly and saves valuable research time.One thing is certain: the knowledge portal answers your questions about the supply chain of medicinal products, active pharmaceutical ingredients and medical devices. You don't have to be an expert. Yet.You will find answers to your questions in the GMP:KnowHow Pharma Logistics (GDP). Where does GDP begin, where does GMP end? What does GDP-compliant mean? When do I also have to take GMP requirements into account? What permits do I need for certain activities? What requirements do I have to fulfil? What is the current legal basis? How am I covered? What authorizations do I have for my work, e.g. from my employer? Who is responsible — the client or the contractor? And many more What is the difference to the GMP Compliance Adviser? GMP:KnowHow Pharma Logistics (GDP) is a practical knowledge portal dedicated to Good Distribution Practice (GDP). It is a product that is independent of the GMP Compliance Adviser and concentrates on content that is essential for carriers of medicinal products, active pharmaceutical ingredients and medical devices as well as for logistics clients. The focus is on practical knowledge and how to apply it in your daily business. If necessary, the relevant regulations can be called up immediately alongside the practical knowledge, and you can see the relevant paragraphs at a glance. In addition, sample documents are available to help you make immediate progress. AuthorSimone Ferrante, currently Director Quality at Fisher Clinical Services, previously served as Head of Quality Control and Responsible Person (GDP) for the Grieshaber Group. She is also a long-standing author and GDP expert at GMP-Verlag.

delivery immediately after receipt of payment

€610.00 net excl. VAT

E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

E-Learning GMP:READY | Specialist Knowledge GMP for Engineers

Why are GMP rules important for technicians and engineers? Technicians and engineers play a key role in ensuring compliance with Good Manufacturing Practice (GMP) standards. They are involved in critical activities such as: planning and construction of ventilation systems, maintenance of water treatment plants, calibration of measuring sensors. Therefore, they are jointly responsible for the quality of medicines and must ensure that their work complies with GMP standards.Your advantages: Fast familiarization with GMP topics in approx. 2 hours, time- and location-independent online training, printable personal certificate, 12-month access for initial and follow-up training, automatic updates in case of legal changes,content compliant with Article 7(4) of Directive 2003/94/EC.The Author This e-learning course was developed with the collaboration of Dipl.-Ing. Andreas Nuhn (D & B Pharmadesign GmbH).

delivery time appr. 2-5 workdays after receipt of payment

€245.00 net excl. VAT

GMP Fundamentals | A Step-by-Step Guide

GMP Fundamentals | A Step-by-Step Guide

This handbook is a practical and easy to read guideline, giving you a quick and comprehensive overview of the complex world of Good Manufacturing Practice (GMP) without the need of previously acquired knowledge. Some topics are: GMP: Purpose and basic pharmaceutical terms Laws, licenses and inspections Personnel: Responsibility and hygiene Standard Operating Procedures (SOP) and documentation Design of rooms and facilities Processing and packaging Quality control and market release Suppliers, storage and logistics (Good Distribution Practice = GDP) Alphabetical index and abbreviations Using practical examples and comparisons to every-day life will help to easy understand GMP regulations.GMP Fundamentals is a helpful guide which facilitates the entry into the GMP world and teaches the necessary basics.

delivery immediately after receipt of payment

€44.90 net excl. VAT

来源:GMP-Verlag LOGFILE Feature · gmp-publishing.com

所属事件

查看事件全部
FDA会议举例:先进隔离设备不等于无菌保障